Cystic Fibrosis Foundation Therapeutics Inc. will award up to $1.7 million to Alaxia SAS to test the safety of a potential inhaled therapy that may fight drug-resistant bacteria that infect people with cystic fibrosis
Site Search
Cystic Fibrosis Foundation Therapeutics Inc. has awarded more than $4 million to AlgiPharma AS to continue Phase 2 clinical trials for a drug that may help restore normal function to cystic fibrosis mucus and make it easier for people with CF to cough out.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $3 million through a drug development award to Swiss pharmaceutical company Polyphor Ltd. to continue clinical trials of a potential anti-inflammatory drug. The drug, POL6014, inhibits the activity of an enzyme that can destroy lung tissue if produced in excess.
The lab will use the latest scientific advances -- including stem cell research and gene editing -- to accelerate new treatments for cystic fibrosis.
The U.S. Food and Drug Administration has approved a device, called RELiZORB®, that helps break down beneficial fats in supplemental nutrition provided via G-tubes.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.
The U.S. Food and Drug Administration approved an important new inhaled
The U.S. Food and Drug Administration (
An advisory panel of the U.S. Food & Drug Administration (
As part of the drug evaluation process, the FDA convened an advisory committee to provide input to the agency on liprotamase, as it does for other drugs.
At today's meeting, data on liprotamase were presented by the FDA and by Eli Lilly and Company, which is developing the drug.
“We appreciate the feedback the committee has provided, and we will continue to work with the FDA to address the questions raised in the meeting as the agency moves toward a final decision on the application,” said Eiry Roberts, M.D., vice president, Autoimmune, Bone-Muscle-Joint, Liprotamase Product Development at Lilly, in a company press statement.
Said Robert J. Beall, Ph.D., president and CEO of the CF Foundation: “We look forward to FDA's final decision and recommendations regarding this drug. We will work with all parties to ensure that safe and effective new drugs are available to CF patients.”
The FDA is expected to rule on liprotamase late this spring.